Fujifilm acquires Biogen Hillerød facility for US$890 million

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Fujifilm acquires Biogen Hillerød facility for US$890 million

Home/Pharma News | Posted 22/03/2019 0 Post your comment

On 12 March 2019, Biogen announced that it had entered into an agreement with Fujifilm Corporation under which Fujifilm will acquire Biogen Manufacturing ApS from Biogen for up to US$890 million in cash. Biogen Manufacturing ApS is a large-scale biologicals manufacturing site located in Hillerød, Denmark (Biogen Hillerød). Biogen Hillerød will become Fujifilm's fourth biopharmaceutical contract development and manufacturing site upon closure of this transaction, which is expected in August 2019 subject to closing conditions. The existing workforce at the site, consisting of approximately 800 employees, will continue employment under Fujifilm.

The Hillerød facility includes a 90,000 L biologicals production facility with assembly, labelling and packing capabilities, quality control laboratories and warehouses. Its acquisition will significantly expand the capacity and capabilities of Fujifilm. In addition, it demonstrates Fujifilm’s commitment to delivering on its strategy to support projects from preclinical through to commercialization, with best in class assets capable of delivering very small to very large production volumes.

As part of the transaction, Biogen will enter into manufacturing services agreements with Fujifilm, under which Fujifilm will use the Hillerød site to produce commercial products for Biogen, such as Tysabri, as well as other third-party products.

‘We continually evaluate our manufacturing strategy and we believe that this agreement serves the best interest of our employees, customers, partners and shareholders’, said Michel Vounatsos, Biogen’s Chief Executive Officer. ‘We believe that we have enhanced our manufacturing capabilities and capacity for biologic[al]s with this transaction. Fujifilm is a well-respected leader in manufacturing biologic[al] products and they share our pioneering culture’.

In May 2017, Fujifilm Kyowa Kirin Biologics announced that its application for approval of its proposed adalimumab biosimilar (FKB327) had been accepted by the European Medicines Agency [1]. In April 2018, it announced that will partner with Mylan to commercialize FKB327 in Europe [2].

Related articles
Fujifilm to acquire cell culture media companies

Fujifilm and Kyowa Hakko Kirin in biosimilars joint venture

References
1. GaBI Online - Generics and Biosimilars Initiative. EMA accepts application for adalimumab biosimilar from Fujifilm Kyowa Kirin Biologics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Mar 22]. Available from: www.gabionline.net/Biosimilars/News/EMA-accepts-application-for-adalimumab-biosimilar-from-Fujifilm-Kyowa-Kirin-Biologics
2. GaBI Online - Generics and Biosimilars Initiative. Mylan and Fujifilm Kyowa Kirin Biologics partner on adalimumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Mar 22]. Available from: www.gabionline.net/Pharma-News/Mylan-and-Fujifilm-Kyowa-Kirin-Biologics-partner-on-adalimumab-biosimilar

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.